Neogen Chemicals Q4 FY25 Earnings Analysis

Published 5 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹5.5K Cr

Price

2,012.8

Market Cap

₹5.5K Cr

P/E Ratio

154.7

Earnings Summary

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

📊 Revenue & Sales Performance

No information is provided regarding the same in the latest conference call.

📈 Profitability & Margins

No information is provided regarding the same in the latest conference call.

🏗️ Capital Expenditure Plans

No information is provided regarding the same in the latest conference call.

💰 Fundraising & Capital Structure

No information is provided regarding the same in the latest conference call.

📋 Order Book & Pipeline

No information is provided regarding the same in the latest conference call.

Key Metrics

Frequently Asked Questions

What were Neogen Chemicals Q4 FY25 results?

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

What is Neogen Chemicals share price analysis?

Neogen Chemicals currently shows a neutral. The stock trades at a P/E of 154.7 with a market cap of ₹5,503. Investors should review the full earnings analysis for detailed insights.

Is Neogen Chemicals planning capital expenditure?

No information is provided regarding the same in the latest conference call.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Others in Chemicals & Petrochemicals this season

  • Archean Chemical Industries Ltd (Q4 FY25)

    Archean Chemical Q4 FY25 quarterly results analysis. - June 2024 quarter marked the lowest sales in 2-3 years; improvement expected going forward with new units

  • Aether Industries Ltd (Q4 FY25)

    Aether Industri. Q4 FY25 quarterly results analysis. - Capacity utilization at Site 2 expected to increase from 62% to around 72% by March 2025, stabilizing at

  • Tatva Chintan Pharma Chem Ltd (Q4 FY25)

    Tatva Chintan Q4 FY25 quarterly results analysis. - Encouraging signs of market recovery with early demand uptick in SDA segment, especially due to hybrid and I

  • Gujarat Fluorochemicals Ltd (Q4 FY25)

    Gujarat Fluoroch Q4 FY25 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹49,338, P/E 83.9.